The Next Phase Of The Obesity Drug Race

Key Concepts

• GLP-1 (Glucagon-like peptide-1): A hormone that regulates appetite and blood sugar; the basis for current blockbuster weight-loss drugs.
• Small Molecule Drugs: Oral medications that are easier to manufacture and distribute compared to injectable peptides.
• Triple Agonist: A drug that activates three distinct hormone receptors (GLP-1, GIP, and glucagon) to maximize weight loss.
• Amylin Analog: A synthetic version of the hormone amylin, which promotes satiety and is being explored for better tolerability.
• Cardiometabolic Health: The broader medical category encompassing obesity, diabetes, and heart-related conditions.
• Bariatric Surgery-level Efficacy: Weight loss results exceeding 30% of total body weight.

---

1. The Evolution of Obesity Treatment

The landscape of obesity treatment has been fundamentally altered by the success of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. Beyond weight loss, these drugs are increasingly utilized to treat comorbidities such as sleep apnea and cardiovascular issues. The industry is now shifting toward a more diversified approach, moving away from viewing obesity as a single condition toward a nuanced model similar to mental health, which requires distinct, specialized medications for different patient needs.

2. The Shift Toward Oral Medications

A major focus of current research is the transition from injectable shots to oral pills.

• Competitive Landscape: Novo Nordisk and Eli Lilly are aggressively marketing their oral GLP-1 candidates.
• Structure Therapeutics: CEO Ray Stevens highlighted their experimental pill, which showed 16% body weight loss in Phase 2 trials. Unlike peptide-based shots, this is a "small molecule" drug, making it easier to produce and more convenient for patients to take daily.
• Strategic Goal: The industry aims to provide oral alternatives that reduce the "daily burden" of managing a chronic disease.

3. Breakthrough Efficacy: Retatrutide

The most significant development discussed is Eli Lilly’s retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors.

• Performance: In clinical trials, patients at the highest dose lost an average of 28% of their body weight, with nearly 50% of participants losing over 30%.
• Clinical Significance: This level of efficacy rivals bariatric surgery. Experts suggest this drug will be particularly vital for patients with a BMI over 40, for whom current treatments may not be sufficient to reach a healthy weight.

4. Improving Tolerability and Convenience

Companies are diversifying their pipelines to address the limitations of current GLP-1 therapies, specifically side effects and dosing frequency.

• Tolerability (Zealand Pharma/Roche): Their drug petrelintide is an amylin analog. While it showed a lower weight loss percentage (11%) compared to GLP-1s, it is being developed with a focus on superior tolerability—specifically reducing vomiting. The company anticipates an "iPhone moment" where patients switch to this drug for a better overall experience.
• Dosing Frequency (Amgen/Pfizer): Amgen is testing maride, an experimental drug that could be administered monthly or even quarterly. The goal is to reduce the psychological burden of frequent injections, which is a primary reason patients discontinue therapy.

5. Key Perspectives and Future Outlook

• Market Competition: As noted by Ray Stevens, the ultimate beneficiary of the intense competition between pharmaceutical giants is the patient, who will gain access to more effective and convenient treatment options.
• Strategic Diversification: Novo Nordisk CEO Mike Dujarric emphasized that the future of the company lies in "cardiometabolics," treating obesity not as a singular weight-loss issue, but as a complex, multi-faceted medical field requiring a wide array of specialized interventions.
• Pipeline Density: With dozens of drugs in the pipeline expected to launch by 2029, the market is moving toward a future where treatments are tailored to specific patient profiles, ranging from those needing extreme weight loss (triple agonists) to those prioritizing ease of use (long-acting injectables or daily pills).

Synthesis

The obesity treatment market is transitioning from a "first-generation" phase dominated by weekly GLP-1 injections to a "second-generation" phase characterized by high-efficacy triple agonists, convenient oral small molecules, and long-acting formulations. The industry is moving toward a patient-centric model that prioritizes not just weight loss, but also tolerability, reduced dosing frequency, and the management of broader cardiometabolic health.